BioSpace News Archive

Siemens Healthineers announced today that its latest critical care testing solution, the RAPIDPoint® 500e Blood Gas Analyzer, has received clearance from the U.S. Food and Drug Administration.

Driven by its Intelligent Cancer Care approach in developing new solutions that use advanced technologies like machine learning, Varian (NYSE: VAR), today announced the newest release of its treatment planning system, Eclipse™ v16

Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the appointment of Abhinav A. Shukla, PhD, as its Chief Technical Operations Officer (CTOO)

Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs

OrphoMed, Inc., a clinical-stage biopharmaceutical company developing first-in-class dimer therapeutics, has paused new patient recruitment for its Phase 2 trial of ORP-101 for treatment of irritable bowel syndrome with diarrhea (IBS-D) in response to the COVID-19 pandemic. Frank J. Steinberg, D.O., Head of Medical Oversight and founding Chief Medical Officer at OrphoMed, notified study sites through the contract resea

S4 Medical, an innovative medical device company focused on protecting the esophagus from damage during catheter ablation procedures, announced that Roy Tanaka has joined its board of directors, rounding out an impressive team.

Executives of NTI Nanotechnology Corp. (“NTI”), headquartered in British Columbia, Canada, made a bold claim today as they released information on a suite of anti-bacterial and anti-viral products

Optime Care, Inc. announced today that it will provide immediate commercial distribution of generic Pyrimethamine 25 mg tablets in the United States. Optime Care is a St. Louis area based, nationally licensed, specialty pharmacy and wholesale distributor. Optime Care will also provide patients and their caregivers with dedicate

New features and complimentary licenses help customers maintain workflow efficiency and revenue integrity during shifting patient volumes

OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to expand the indications for its RESPONSE™ Scoliosis System to include neuromuscular implants.